How to buy Bionomics shares
Own Bionomics shares in just a few minutes.
Bionomics Limited is a biotechnology business based in Australia. Bionomics shares (BNO) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Bionomics has a trailing 12-month revenue of around $3.2 million.
How to buy shares in Bionomics
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Bionomics. Find the share by name or ticker symbol: BNO. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bionomics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $N/A, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Bionomics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Bionomics share priceUse our graph to track the performance of BNO stocks over time.
Bionomics shares at a glance
|52-week range||AUDA$0.03 - AUDA$0.185|
|50-day moving average||AUDA$0.1305|
|200-day moving average||AUDA$0.0733|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||AUDA$-0.02|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Bionomics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Bionomics under- or over-valued?
Valuing Bionomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bionomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bionomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $255,158.
The EBITDA is a measure of a Bionomics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.2 million|
|Gross profit TTM||$-2,635,298|
|Return on assets TTM||-11.5%|
|Return on equity TTM||-39.88%|
|Market capitalisation||$112.8 million|
TTM: trailing 12 months
Bionomics share dividends
We're not expecting Bionomics to pay a dividend over the next 12 months.
Have Bionomics's shares ever split?
Bionomics's shares were split on 1 March 2004.
Bionomics share price volatility
Over the last 12 months, Bionomics's shares have ranged in value from as little as $0.03 up to $0.185. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Bionomics's is 2.8452. This would suggest that Bionomics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.
Frequently asked questions
Ask an Expert